Log in

Relevant bibliographies by topics / Novel targeted therapies / Journal articles

To see the other types of publications on this topic, follow the link: Novel targeted therapies.

Journal articles on the topic 'Novel targeted therapies'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Novel targeted therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

St Clair, E. William. "Novel targeted therapies for autoimmunity." Current Opinion in Immunology 21, no. 6 (2009): 648–57. http://dx.doi.org/10.1016/j.coi.2009.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Karpel-Massler, Georg, Trang T. T. Nguyen, Enyuan Shang, and Markus D. Siegelin. "Novel IDH1-Targeted Glioma Therapies." CNS Drugs 33, no. 12 (2019): 1155–66. http://dx.doi.org/10.1007/s40263-019-00684-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Giudice, Valentina, Carmine Vecchione, and Carmine Selleri. "Cardiotoxicity of Novel Targeted Hematological Therapies." Life 10, no. 12 (2020): 344. http://dx.doi.org/10.3390/life10120344.

Full text

Abstract:

Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways

APA, Harvard, Vancouver, ISO, and other styles

4

Fullmer, Amber, Hagop Kantarjian, and Elias Jabbour. "Novel and Targeted Therapies in Leukemia." Emerging Cancer Therapeutics 2, no. 2 (2011): 389–409. http://dx.doi.org/10.5003/2151-4194.2.2.389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Maron, Steven B., and Daniel V. T. Catenacci. "Novel Targeted Therapies for Esophagogastric Cancer." Surgical Oncology Clinics of North America 26, no. 2 (2017): 293–312. http://dx.doi.org/10.1016/j.soc.2016.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hideshima, Teru, and Kenneth C. Anderson. "Preclinical Studies of Novel Targeted Therapies." Hematology/Oncology Clinics of North America 21, no. 6 (2007): 1071–91. http://dx.doi.org/10.1016/j.hoc.2007.08.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lane, N. "Novel and targeted therapies for OA." Osteoarthritis and Cartilage 20 (April 2012): S3. http://dx.doi.org/10.1016/j.joca.2012.02.613.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Konda, Bhavana, and Lawrence S. Kirschner. "Novel targeted therapies in adrenocortical carcinoma." Current Opinion in Endocrinology & Diabetes and Obesity 23, no. 3 (2016): 233–41. http://dx.doi.org/10.1097/med.0000000000000247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Argilés, Josep M., Francisco Javier López-Soriano, Britta Stemmler, and Sílvia Busquets. "Novel targeted therapies for cancer cachexia." Biochemical Journal 474, no. 16 (2017): 2663–78. http://dx.doi.org/10.1042/bcj20170032.

Full text

Abstract:

Anorexia and metabolic alterations are the main components of the cachectic syndrome. Glucose intolerance, fat depletion, muscle protein catabolism and other alterations are involved in the development of cancer cachexia, a multi-organ syndrome. Nutritional approach strategies are not satisfactory in reversing the cachectic syndrome. The aim of the present review is to deal with the recent therapeutic targeted approaches that have been designed to fight and counteract wasting in cancer patients. Indeed, some promising targeted therapeutic approaches include ghrelin agonists, selective androgen

APA, Harvard, Vancouver, ISO, and other styles

10

Macfarlane, Robyn J., and Kim N. Chi. "Novel Targeted Therapies for Prostate Cancer." Urologic Clinics of North America 37, no. 1 (2010): 105–19. http://dx.doi.org/10.1016/j.ucl.2009.11.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Nishio, Shin. "Novel Targeted Therapies in Uterine Carcinosarcomas." Annals of Oncology 30 (October 2019): vi50. http://dx.doi.org/10.1093/annonc/mdz340.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Sendur, Mehmet A. N., Sercan Aksoy, and Kadri Altundag. "Cardiotoxicity of novel HER2-targeted therapies." Current Medical Research and Opinion 29, no. 8 (2013): 1015–24. http://dx.doi.org/10.1185/03007995.2013.807232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Iams, Wade T., Jeffrey A. Sosman, and Sunandana Chandra. "Novel Targeted Therapies for Metastatic Melanoma." Cancer Journal 23, no. 1 (2017): 54–58. http://dx.doi.org/10.1097/ppo.0000000000000242.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Wechsler, Michael E., Patricia C. Fulkerson, Bruce S. Bochner, et al. "Novel targeted therapies for eosinophilic disorders." Journal of Allergy and Clinical Immunology 130, no. 3 (2012): 563–71. http://dx.doi.org/10.1016/j.jaci.2012.07.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rizzo, Alessandro, and Giovanni Brandi. "Novel Targeted Therapies for Advanced Cholangiocarcinoma." Medicina 57, no. 3 (2021): 212. http://dx.doi.org/10.3390/medicina57030212.

Full text

Abstract:

Cholangiocarcinoma (CCA) includes a group of rare and aggressive hepatobiliary malignancies, including extrahepatic cholangiocarcinoma (eCCA) and intrahepatic cholangiocarcinoma (iCCA), with the former further subdivided into distal (dCCA) and perihilar cholangiocarcinoma (pCCA) [...]

APA, Harvard, Vancouver, ISO, and other styles

16

Portell, Craig A., and Anjali S. Advani. "Novel targeted therapies in acute lymphoblastic leukemia." Leukemia & Lymphoma 55, no. 4 (2013): 737–48. http://dx.doi.org/10.3109/10428194.2013.823493.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Murayama, Yoko, Kenji Oritani, and Shusaku Tsutsui. "Novel CD9-targeted therapies in gastric cancer." World Journal of Gastroenterology 21, no. 11 (2015): 3206–13. http://dx.doi.org/10.3748/wjg.v21.i11.3206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Coskun, Mehmet, Severine Vermeire, and Ole Haagen Nielsen. "Novel Targeted Therapies for Inflammatory Bowel Disease." Trends in Pharmacological Sciences 38, no. 2 (2017): 127–42. http://dx.doi.org/10.1016/j.tips.2016.10.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Schmitzâ©, Shu-Fang Hsu. "Novel clinical trial designs for targeted therapies." Int. Journal of Clinical Pharmacology and Therapeutics 55, no. 08 (2017): 695–97. http://dx.doi.org/10.5414/cpxces15ea08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lin, C. C., and K. P. Papadopoulos. "Novel targeted therapies for advanced esophageal cancer." Diseases of the Esophagus 20, no. 5 (2007): 365–71. http://dx.doi.org/10.1111/j.1442-2050.2007.00730.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Alinari, Lapo, Beth Christian, and Robert A. Baiocchi. "Novel targeted therapies for mantle cell lymphoma." Oncotarget 3, no. 2 (2012): 203–11. http://dx.doi.org/10.18632/oncotarget.426.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Jazieh, Khalid, Ruth Bell, Nayan Agarwal, and Jame Abraham. "Novel targeted therapies for metastatic breast cancer." Annals of Translational Medicine 8, no. 14 (2020): 907. http://dx.doi.org/10.21037/atm.2020.03.43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Johnston, Stephen R. D., Alexandra Leary, Lesley-Ann Martin, Ian E. Smith, and Mitch Dowsett. "Enhancing endocrine response with novel targeted therapies." Cancer 112, S3 (2008): 710–17. http://dx.doi.org/10.1002/cncr.23190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cristofanilli, Massimo. "Novel targeted therapies in inflammatory breast cancer." Cancer 116, S11 (2010): 2837–39. http://dx.doi.org/10.1002/cncr.25172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Waldner, Maximilian J., and Markus F. Neurath. "Novel cytokine-targeted therapies and intestinal inflammation." Current Opinion in Pharmacology 9, no. 6 (2009): 702–7. http://dx.doi.org/10.1016/j.coph.2009.07.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Mattiuzzi, Camilla, Emmanuel Favaloro, and Giuseppe Lippi. "Novel and Emerging Therapies: Thrombus-Targeted Fibrinolysis." Seminars in Thrombosis and Hemostasis 39, no. 01 (2012): 048–58. http://dx.doi.org/10.1055/s-0032-1328935.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Shah, Rashmi R., and Giuseppe Curigliano. "Safety of Novel Targeted Therapies in Oncology." Drug Safety 42, no. 2 (2019): 157–58. http://dx.doi.org/10.1007/s40264-018-0770-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Leow, Christopher Chang-Yew, and Michael Sze Yuan Low. "Targeted Therapies for Multiple Myeloma." Journal of Personalized Medicine 11, no. 5 (2021): 334. http://dx.doi.org/10.3390/jpm11050334.

Full text

Abstract:

Multiple myeloma continues to be a challenging disorder to treat despite improved therapies and the widespread use of proteasome inhibitors and immunomodulatory drugs. Although patient outcomes have improved, the disease continues to invariably relapse, and in the majority of cases, a cure remains elusive. In the last decade, there has been an explosion of novel drugs targeting cellular proteins essential for malignant plasma cell proliferation and survival. In this review, we focus on novel druggable targets leading to the development of monoclonal antibodies and cellular therapies against su

APA, Harvard, Vancouver, ISO, and other styles

29

Perry, James, Masahiko Okamoto, Michael Guiou, Katsuyuki Shirai, Allison Errett, and Arnab Chakravarti. "Novel Therapies in Glioblastoma." Neurology Research International 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/428565.

Full text

Abstract:

Conventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent improved understanding of basic tumor biology, targeted therapies have become cornerstones for cancer treatment. Many pathways (RTKs, PI3K/AKT/mTOR, angiogenesis, etc.) have been identified in GBM as playing major roles in tumorigenesis, treatment resistance, or natural history of disease. Despite the gr

APA, Harvard, Vancouver, ISO, and other styles

30

Luis, Michael. "Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies." World Journal of Gastroenterology 19, no. 38 (2013): 6383. http://dx.doi.org/10.3748/wjg.v19.i38.6383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

De Paoli, Paolo. "Novel Virally Targeted Therapies of EBV-Associated Tumors." Current Cancer Drug Targets 8, no. 7 (2008): 581–96. http://dx.doi.org/10.2174/156800908786241069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Finnberg, Niklas, Prashanth Gokare, and Wafik El-Deiry. "Novel and Emerging Targeted Therapies of Colorectal Cancer." Current Clinical Pharmacology 10, no. 4 (2015): 279–98. http://dx.doi.org/10.2174/1574884710666151020095911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bellmunt, J., M. Hussain, and C. P. Dinney. "Novel approaches with targeted therapies in bladder cancer." Critical Reviews in Oncology/Hematology 46 (June 2003): 85–104. http://dx.doi.org/10.1016/s1040-8428(03)00067-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Herbst, R. S. "Role of novel targeted therapies in the clinic." British Journal of Cancer 92, S1 (2005): S21—S27. http://dx.doi.org/10.1038/sj.bjc.6602605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Farley, John, and Peter G. Rose. "Trial design for evaluation of novel targeted therapies." Gynecologic Oncology 116, no. 2 (2010): 173–76. http://dx.doi.org/10.1016/j.ygyno.2009.09.046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Perez, Cesar A., Edgardo S. Santos, Belisario A. Arango, Luis E. Raez, and Ezra E. W. Cohen. "Novel molecular targeted therapies for refractory thyroid cancer." Head & Neck 34, no. 5 (2011): 736–45. http://dx.doi.org/10.1002/hed.21755.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Konecny, Gottfried E. "Challenges in the Development of Novel Targeted Therapies." Breast Care 2, no. 2 (2007): 64–66. http://dx.doi.org/10.1159/000101529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ferreira, Mariana B. A., João Paulo S. N. Lima, and Ezra E. W. Cohen. "Novel targeted therapies in head and neck cancer." Expert Opinion on Investigational Drugs 21, no. 3 (2012): 281–95. http://dx.doi.org/10.1517/13543784.2012.651455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Bagia, Mamta, and Anna K. Nowak. "Novel Targeted Therapies and Vaccination Strategies for Mesothelioma." Current Treatment Options in Oncology 12, no. 2 (2011): 149–62. http://dx.doi.org/10.1007/s11864-011-0149-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Di Bella, Sara, Filippo Venturini, Giovanna Marrapese, Emiliana Tarenzi, and Salvatore Siena. "Cardiotoxicity of novel molecular targeted therapies of cancer." Journal of Cardiovascular Echography 21, no. 2 (2011): 78–85. http://dx.doi.org/10.1016/j.jcecho.2011.05.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Belani, Chandra P. "Novel Targeted Therapies: A Challenge for Drug Development." Clinical Lung Cancer 5 (September 2003): S4. http://dx.doi.org/10.3816/clc.2003.s.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

de la Puente, Pilar, Barbara Muz, Feda Azab, Micah Luderer, and Abdel Kareem Azab. "Molecularly Targeted Therapies in Multiple Myeloma." Leukemia Research and Treatment 2014 (April 16, 2014): 1–8. http://dx.doi.org/10.1155/2014/976567.

Full text

Abstract:

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients will eventually relapse or become refractory to the treatments. Although the treatments have improved, the major problem in MM is the resistance to therapy. Novel agents are currently in development for the treatment of relapsed/refractory MM, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cell signaling targeted therapies, and strategies targeting the tumor microenvironment. We have previously reviewed in detail the contemporary immunomodulatory drugs, proteasome i

APA, Harvard, Vancouver, ISO, and other styles

43

Hengartner, Astrid C., Eric Prince, Trinka Vijmasi, and Todd C. Hankinson. "Adamantinomatous craniopharyngioma: moving toward targeted therapies." Neurosurgical Focus 48, no. 1 (2020): E7. http://dx.doi.org/10.3171/2019.10.focus19705.

Full text

Abstract:

The evolving characterization of the biological basis of adamantinomatous craniopharyngioma (ACP) has provided insights critical for novel systemically delivered therapies. While current treatment strategies for ACP are associated with low mortality rates, patients experience severely lowered quality of life due to high recurrence rates and chronic sequelae, presenting a need for novel effective treatment regimens. The identification of various dysregulated pathways that play roles in the pathogenesis of ACP has prompted the investigation of novel treatment options. Aberrations in the CTNNB1 g

APA, Harvard, Vancouver, ISO, and other styles

44

Sharma, Puja, and Waldemar Debinski. "Receptor-Targeted Glial Brain Tumor Therapies." International Journal of Molecular Sciences 19, no. 11 (2018): 3326. http://dx.doi.org/10.3390/ijms19113326.

Full text

Abstract:

Among primary brain tumors, malignant gliomas are notably difficult to manage. The higher-grade tumors represent an unmet need in medicine. There have been extensive efforts to implement receptor-targeted therapeutic approaches directed against gliomas. These approaches include immunotherapies, such as vaccines, adoptive immunotherapy, and passive immunotherapy. Targeted cytotoxic radio energy and pro-drug activation have been designed specifically for brain tumors. The field of targeting through receptors progressed significantly with the discovery of an interleukin 13 receptor alpha 2 (IL-13

APA, Harvard, Vancouver, ISO, and other styles

45

Pozdnyakova, Olga, Jeffery L. Kutok, and Scott J. Rodig. "Emerging Targeted Therapies for Lymphoid Malignancies." Archives of Pathology & Laboratory Medicine 136, no. 5 (2012): 476–82. http://dx.doi.org/10.5858/arpa.2010-0391-ra.

Full text

Abstract:

Context.—Our understanding of molecular events in the pathogenesis of hematologic malignancies has evolved substantially. The research data gathered in the past 3 decades have led to the definition of neoplastic disorders based on specific genetic and molecular alterations, which is reflected in the current World Health Organization's classification of tumors of hematopoietic and lymphoid tissues. Moreover, there have been dramatic successes in the development and implementation of therapies that specifically target the proteins and signaling cascades affected by tumor-specific genetic alterat

APA, Harvard, Vancouver, ISO, and other styles

46

Alvarez, Ricardo H., Vicente Valero, and Gabriel N. Hortobagyi. "Emerging Targeted Therapies for Breast Cancer." Journal of Clinical Oncology 28, no. 20 (2010): 3366–79. http://dx.doi.org/10.1200/jco.2009.25.4011.

Full text

Abstract:

Increased understanding of the molecular events involved in cancer development has led to the identification of a large number of novel targets and, in parallel, to the development of multiple approaches to anticancer therapy. Targeted therapy focuses on specific molecules in the malignant cell signal transduction machinery, including crucial molecules involved in cell invasion, metastasis, apoptosis, cell-cycle control, and tumor-related angiogenesis. In breast cancer, two new targeted agents have recently been approved: lapatinib, directed against the human epidermal growth factor receptor 2

APA, Harvard, Vancouver, ISO, and other styles

47

Renouf, Daniel J., Juan P. Velazquez-Martin, Rand Simpson, Lillian L. Siu, and Philippe L. Bedard. "Ocular Toxicity of Targeted Therapies." Journal of Clinical Oncology 30, no. 26 (2012): 3277–86. http://dx.doi.org/10.1200/jco.2011.41.5851.

Full text

Abstract:

Molecularly targeted agents are commonly used in oncology practice, and many new targeted agents are currently being tested in clinical trials. Although these agents are thought to be more specific and less toxic then traditional cytotoxic chemotherapy, they are associated with a variety of toxicities, including ocular toxicity. Many of the molecules targeted by anticancer agents are also expressed in ocular tissues. We reviewed the literature for described ocular toxicities associated with both approved and investigational molecularly targeted agents. Ocular toxicity has been described with n

APA, Harvard, Vancouver, ISO, and other styles

48

Agarwal, Gautum, Shilpa Gupta, and Philippe E. Spiess. "Novel targeted therapies for the treatment of penile cancer." Expert Opinion on Drug Discovery 9, no. 8 (2014): 959–68. http://dx.doi.org/10.1517/17460441.2014.925875.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Radonjic-Hoesli, Susanne, Peter Valent, Amy D. Klion, Michael E. Wechsler, and Hans-Uwe Simon. "Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy." Annual Review of Pharmacology and Toxicology 55, no. 1 (2015): 633–56. http://dx.doi.org/10.1146/annurev-pharmtox-010814-124407.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Smith, Philip W., Chadrick E. Denlinger, and David R. Jones. "Novel Targeted Therapies for Non–Small Cell Lung Cancer." Thoracic Surgery Clinics 16, no. 4 (2006): 353–66. http://dx.doi.org/10.1016/j.thorsurg.2006.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!